for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Infant Bacterial Therapeutics AB

IBTb.ST

Latest Trade

181.40SEK

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

115.00

 - 

274.50

As of on the Stockholm Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
181.40
Open
--
Volume
--
3M AVG Volume
0.34
Today's High
--
Today's Low
--
52 Week High
274.50
52 Week Low
115.00
Shares Out (MIL)
11.23
Market Cap (MIL)
1,952.72
Forward P/E
-32.55
Dividend (Yield %)
--

Next Event

Q3 2019 Infant Bacterial Therapeutics AB Earnings Release

Latest Developments

More

Infant Bacterial Therapeutics Q2 Operating Loss At SEK 8.0 Million

FDA And Infant Bacterial Therapeutics Agree On Design Of Phase III Study

Infant Bacterial Therapeutics Q1 Operating Loss Narrows To SEK 0.9 Mln

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Infant Bacterial Therapeutics AB

Infant Bacterial Therapeutics AB is a Sweden-based company, which is primarily involved in the pharmaceutical industry. The Company develops drugs that meet the needs of the premature infant. The Company’s focus is on clinical development of IBP-9414, a drug candidate containing Lactobacillus reuteri, in the prevention of necrotizing enterocolitis (NEC), a fatal disease that affects premature infants.

Industry

Biotechnology & Drugs

Contact Info

Gamla Brogatan 11

+46.8.41014555

http://ibtherapeutics.com/

Executive Leadership

Peter Rothschild

Chairman of the Board

Staffan Stromberg

Chief Executive Officer

Daniel Mackey

Chief Financial Officer

Anders Kronstrom

Chief Technical Officer

Eamonn Connolly

Head of Research & Development

Key Stats

2.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, SEK)

2019(E)

0.0K
EPS (SEK)

2019(E)

-5.530
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
3.68
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-7.09
Return on Equity (TTM)
-6.99

Latest News

Latest News

BRIEF-Infant Bacterial Therapeutics AB Announces First Distribution Agreement

* SIGNED FIRST DISTRIBUTION AGREEMENT FOR IBP-9414 WITH MEGAPHARM LTD. FOR THE ISRAELI MARKET AND THE PALESTINIAN AUTHORITY'S TERRITORIES

BRIEF-Infant Bacterial Therapeutics Q4 Operating Loss Narrows To Sek 9.1 Mln

* Q4 OPERATING LOSS SEK 9.1 MILLION VERSUS LOSS SEK 14.1 MILLION YEAR AGO

BRIEF-IBT Raises About SEK 440 Million In Rights Issue

* RIGHTS ISSUE FOR IBT'S SHAREHOLDERS HAS BEEN FULLY SUBSCRIBED

BRIEF-Infant Bacterial Therapeutics announces capital raise

* REG-INFANT BACTERIAL THERAPEUTICS ANNOUNCES CAPITAL RAISE OF APPROXIMATELY SEK 545 MILLION IN TOTAL

BRIEF-Infant Bacterial Therapeutics Q3 operating loss narrows to SEK 4.6 mln

* Q3 OPERATING LOSS SEK 4.6 MILLION VERSUS LOSS SEK 7.9 MILLION YEAR AGO Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-EMA adopts positive opinion on paediatric investigation plan for IBT's lead product

* REG-EUROPEAN MEDICINES AGENCY (EMA) ADOPTS A POSITIVE OPINION ON THE PAEDIATRIC INVESTIGATION PLAN FOR IBT'S LEAD PRODUCT

BRIEF-Infant Bacterial Therapeutics Q2 oper loss at SEK 13.8 mln

* Q2 OPERATING LOSS -13 826 KSEK (-10 975) Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Infant Bacterial Therapeutics Jan-Mar operating loss widens to SEK 8.6 mln

* JAN-MAR OPERATING LOSS SEK 8.6 MILLION VERSUS SEK 5.1 MILLION YEAR AGO Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Infant Bacterial Therapeutics H2 operating loss widens to SEK 22.0 mln

* H2 operating loss 22.0 million Swedish crowns ($2.47 million) versus loss 10.9 million crowns year ago Source text for Eikon: Further company coverage: ($1 = 8.9210 Swedish crowns) (Gdynia Newsroom)

BRIEF-Infant Bacterial Therapeutics appoints Daniel Mackey new CFO

* Names Daniel Mackey as Chief Financial Officer from Jan. 2017

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up